Adamax

It's a structural derivative - Semax's Ac-MEHFPGP core plus an Ala-Gly tail capped with an adamantyl group borrowed from P-21. Same primary mechanism (BDNF / TrkB / D2 modulation), but the adamantane modification is hypothesized to improve blood-brain-barrier penetration and extend the subjective duration of effect to roughly 2-3 days vs Semax's ~30-60 minute serum half-life. No pharmacokinetic data exist for Adamax, so this is a community-reported difference in duration, not a measured one. The pharmacology is similar in kind, different in duration.

Adamax was first synthesized by Ceretropic (a research-peptide vendor) circa 2016, not a Russian academic institute, so it never entered the formal Semax / Selank publication pipeline. The Russian Institute of Molecular Genetics RAS is responsible for Semax and Selank - but they did not develop Adamax. Effects are extrapolated from Semax data and community reports; primary literature under the 'Adamax' name does not exist as of 2026.

Both are documented. Subcutaneous is more common in current research protocols because the adamantyl tail makes the molecule larger and more lipophilic than parent Semax, which slows nasal absorption. Intranasal protocols exist but require higher doses to achieve comparable central effects. Subcutaneous at 500-1500 mcg every other day is the dominant community pattern.

Semax is typically dosed daily (often multiple times per day) because of its short serum half-life. Adamax community protocols describe a subjectively long duration of effect (~2-3 days), supporting every-other-day or 3x/week dosing; note there are no pharmacokinetic or receptor-occupancy data behind this. Daily dosing is not necessary and may increase the risk of D2 receptor desensitization without proportionate benefit.

Caution. All three modulate overlapping receptor systems (BDNF / TrkB / D2). Simultaneous full-dose stacking has not been characterized in any controlled setting and risks additive receptor desensitization. If combining, conservative low-dose protocols and longer washout windows between cycles are sensible. Adamax + Selank is a more common pairing because the mechanisms (BDNF / D2 vs GABAergic / serotonergic anxiolysis) are complementary rather than overlapping.

A typical research cycle is 4-8 weeks with at least a 2-week washout. Beginners start at 500 mcg subcutaneous every other day to assess tolerance. Intermediate users move to 750-1000 mcg three times per week. Advanced protocols cap around 1500-2000 mcg every other day. Effects build over the first 1-2 weeks; subjective plateau is typically reported at weeks 3-4.

There are no formal toxicology studies. Anecdotal reports cite mild side effects similar to Semax: headache (often dose-related), transient insomnia if dosed in the evening, occasional irritability or mild mood elevation. No reports of serious adverse events in the public community datasets - but this reflects underreporting in unregulated use, not formal safety clearance. Avoid in pregnancy, lactation, active psychiatric instability, and uncontrolled hypertension.